Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF5C2I
|
|||
| Drug Name |
RIPA-56
|
|||
| Synonyms |
1956370-21-0; N-benzyl-N-hydroxy-2,2-dimethylbutanamide; CHEMBL4092421; GTPL9643; SCHEMBL17874088; EX-A4338; BDBM50229025; MFCD30738006; s6511; ZINC616570725; CS-6266; compound 92 [WO2016101885]; compound 56 [PMID: 27992216]; HY-101032; C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O; A1-28956
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-alcoholic fatty liver disease [ICD-11: DB92; ICD-10: K76.0; ICD-9: 571.8] | Investigative | [1] | |
| Company |
National Institute of Biological Sciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H19NO2
|
|||
| Canonical SMILES |
CCC(C)(C)C(=O)N(CC1=CC=CC=C1)O
|
|||
| InChI |
1S/C13H19NO2/c1-4-13(2,3)12(15)14(16)10-11-8-6-5-7-9-11/h5-9,16H,4,10H2,1-3H3
|
|||
| InChIKey |
AVYVHIKSFXVDBG-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Receptor-interacting protein 1 (RIPK1) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.